Golidocitinib Receives National Approval for Adult Patients with Relapsed T-Cell Lymphoma
Golidocitinib, a first-in-class selective Janus kinase 1 (JAK1) inhibitor, has received approval from the National Medical Products Administration of China for the treatment of adult patients with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL).
PTCL encompasses a diverse range of aggressive non-Hodgkin lymphomas, and patients face a high risk of disease relapse, even after achieving remission from initial treatments.
The prognosis for patients with r/r PTCL remains poor, with a three-year survival rate of only 23% and a median overall survival of 5.8 months.
Its approval assessed safety and efficacy as a monotherapy in r/r PTCL. It demonstrated strong and long-lasting effectiveness against tumors, with a 44.3% overall response rate, including a 23.9% complete response rate. Tumor responses were observed across various subtypes of PTCL.
Dizal pioneered the development of Golidocitinib, targeting the JAK/STAT pathway, which has proven to be a promising therapeutic approach for PTCL. With a selectivity of over 200 to 400 times compared to other JAK members and optimal pharmacokinetic properties, this demonstrates potent anti-tumour efficacy while maintaining a favourable safety profile.
The drug has shown effective anti-tumour activity across different PTCL subtypes, distinguishing it from other targeted therapies.
